Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab
Maria Laura Canale(Ospedale Versilia), Andrea Camerini(Ospedale Versilia), Elio Venturini(Azienda Usl Toscana Centro), C. Puccetti(Ospedale Versilia), Nicola Maurea(Cancer Institute (WIA)), Fabio Maria Turazza, D. Amoroso(Ospedale Versilia), Giancarlo Casolo(Fondazione Toscana Gabriele Monasterio), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Sara Donati(Ospedale Versilia)
Cited by 2
Related Papers
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Detection of Significant Coronary Artery Disease by Noninvasive Anatomical and Functional Imaging
|Circulation Cardiovascular Imaging|2015|412
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116